PAVmed unit Lucid Diagnostics wins Concert commercial coverage policy for EsoGuard test
LUCD•EsoGuard singled out under coverage criteria
Concert flagged EsoGuard as the only esophageal precancer test meeting its coverage criteria. Multiple client health plans have adopted the policy.
Concert issues commercial coverage policy for EsoGuard
PAVmed subsidiary Lucid Diagnostics won a positive Concert commercial coverage policy for its EsoGuard esophageal DNA test, effective July 2026.
The policy deems EsoGuard medically necessary for patients meeting American College of Gastroenterology screening criteria for esophageal precancer and cancer.
